PHASE I STUDY OF VELIPARIB IN COMBINATION WITH GEMCITABINE

BACKGROUND: Veliparib (ABT-888) is an oral PARP inhibitor expected to increase gemcitabine activity. This phase I determined the maximal tolerable dose (MTD), dose-limiting toxicities (DLT), antitumor activity, pharmacokinetics (PK), and pharmacodynamics (PD) of veliparib combined with gemcitabine....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Chemother Pharmacol
Glavni autori: Stoller, Ronald, Schmitz, John C., Ding, Fei, Puhalla, Shannon, Belani, Chandra P., Appleman, Leonard, Lin, Yan, Jiang, Yixing, Almokadem, Salah, Petro, Daniel, Holleran, Julianne, Kiesel, Brian F., Czambel, R. Ken, Carneiro, Benedito A., Kontopodis, Emmanuel, Hershberger, Pamela A., Rachid, Madani, Chen, Alice, Chu, Edward, Beumer, Jan H
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5734661/
https://ncbi.nlm.nih.gov/pubmed/28770300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3409-3
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items